Tag: 1001

Applied Manufacturing Technologies and FANUC to Highlight Collaborative Mixed-Load Handling at Automate 2026

AMT's demonstration in FANUC booth #1001 combines collaborative robotics and AI-enabled vision technology for mixed-load palletizing and depalletizing applications in warehouse and logistics environments.ORION,...

AMGEN PRESENTS NEW DATA ACROSS ITS CARDIOMETABOLIC PORTFOLIO AT AMERICAN DIABETES ASSOCIATION 86TH SCIENTIFIC SESSIONS

VESALIUS-CV Subgroup Results Show Repatha® Reduces Risk of First Major Cardiovascular Events by 29% in People Living with High-Risk DiabetesNew Real-World Data Highlight Treatment...

Santhera Secures Agreement with GEN for the Distribution of AGAMREE® (Vamorolone) in Türkiye

Pratteln, Switzerland, 13 August, 2025 – Santhera Pharmaceuticals (SIX: SANN) announces the signing of an exclusive agreement with Gen İlaç ve Sağlık Ürünleri San. ve Tic. A.Ş. (GEN) for the distribution and promotion of AGAMREE® (vamorolone) in Türkiye for the treatment of Duchenne muscular dystrophy (DMD) in patients four years of age and older.

Orla Mining Reports New Drill Results from Zone 22 at Camino Rojo, Mexico

High grade intersections outside current resource panels enhances potential VANCOUVER, BC, Aug. 7, 2025 /CNW/ - Orla Mining Ltd. (TSX: OLA) (NYSE: ORLA) ("Orla" or...

Renault Group strengthens its presence in India to support its international ambitions

Renault Group strengthens its presence in India to support its international ambitions

SAFE – Chiffre d’affaires du premier semestre 2025 : 2,5 M€

Chiffre d’affaires du premier semestre 2025 : 2,5 M€

Nissan’s contribution to Renault Group’s second quarter 2025 earnings

Nissan’s contribution to Renault Group’s second quarter 2025 earnings

BlueSphere Bio CSO Alan Korman Recipient of Esteemed 2025 William B. Coley Award

Alan Korman honored in the category of tumor immunology for foundational role in checkpoint inhibitors PITTSBURGH, July 29, 2025 /PRNewswire/ -- BlueSphere Bio, a clinical...

Donanemab receives positive opinion from the Committee for Medicinal Products for Human Use (CHMP) in early symptomatic Alzheimer’s disease

The opinion will now be referred to the European Commission for final regulatory decision on donanemab INDIANAPOLIS, July 25, 2025 /PRNewswire/ -- Eli Lilly and...

H1 2025 financial figures and FY 2025 financial outlook

H1 2025 financial figures and FY 2025 financial outlook

Neurona Announces Publication in Neuron Reporting Durable Preclinical Engraftment of Human Interneuron Cell Therapy

Earendil Labs announces initiation of a phase 1 study of a half-life extended novel anti-TL1A antibody

MIDDLETOWN, Del., July 10, 2025 /PRNewswire/ -- Earendil Labs, an AI-empowered biotechnology company, announced that it has completed cohort 1 dosing in a phase...

Genfit: Half-Year Report of Liquidity Contract with Crédit Industriel et Commercial

Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), July 8, 2025 - GENFIT (Nasdaq and Euronext: GNFT), a biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced the half-year report of the liquidity contract with Crédit Industriel et Commercial.

Genfit : Bilan semestriel du contrat de liquidité contracté avec le Crédit Industriel et Commercial

Lille (France), Cambridge (Massachusetts, États-Unis), Zurich (Suisse), le 8 juillet 2025 – GENFIT (Nasdaq et Euronext: GNFT), société biopharmaceutique engagée dans l’amélioration de la vie des patients atteints de maladies rares du foie pouvant engager le pronostic vital, annonce aujourd’hui le bilan semestriel du contrat de liquidité contracté avec le Crédit Industriel et Commercial.

Tencent Cloud, UXSoft, and BAPE Hong Kong Limited Collaborate to Power Global Retail Infrastructure for A Bathing Ape®

PIS Showcases Global Growth Strategy & Expansion Plan at Posidonia 2026

Age is just a Number. Mobility is a Choice.